Endothelial progenitor cell impairment mediated vasodilation dysfunction via diminishing nitric oxide production in postmenopausal females

WAN-ZHOU WU1*, DA-JUN HU1,2*, ZHEN-YU WANG1, LONG-SHENG LIAO1 and CHUAN-CHANG LI1

1Department of Geriatric Medicine, Xiangya Hospital, Central South University, Changsha, Hunan 410078; 2Department of Cardiovascular Medicine, First People’s Hospital of Chenzhou, Chenzhou, Hunan 423000, P.R. China

Received May 10, 2018; Accepted November 28, 2018

DOI: 10.3892/mmr.2019.9888

Abstract. Vascular endothelial dysfunction is the major contributing factor to hypertension. Endothelial progenitor cells (EPCs) are essential for endogenous vascular endothelial renovation. The activity and number of circulating EPCs are preserved in prehypertensive premenopausal females according to our previous research. However, the changes of EPCs in prehypertensive postmenopausal females are poorly understood, and the mechanisms responsible for the loss of the gender protection advantage of cardiovascular disease remain unexplored. In order to determine the effects of EPCs in prehypertensive postmenopausal females, the number and activity of circulating EPCs were tested in the present study. Next, the function of EPCs secreting nitric oxide (NO), vascular endothelial growth factor (VEGF) and granulocyte-macrophage colony-stimulating factor (GM-CSF), as well as their concentration in the plasma, were measured. The association between flow-mediated dilation (FMD) and EPC secretion was also assessed. Attenuation of proliferation and migration of EPCs was observed in prehypertensive patients in comparison with normotensive subjects. In addition, a reduced NO production secreted by EPCs was detected in prehypertensive patients as compared with that in normotensive patients. There was no significant difference in EPC function between postmenopausal females and age-matched males. Finally, the association between FMD and NO production was validated. Collectively, these data indicated that impaired EPCs mediated vasodilation dysfunction via decreasing NO production. Therefore, EPC function enhancement and NO level augmentation are emerging as novel therapeutic strategies for prehypertension therapy.

Introduction

Prehypertension is the intermediate period prior to the pathogenesis of hypertension, as proposed by the seventh report of the Joint National Committee (JNC) in 2003 (1). It is defined as a systolic blood pressure (SBP) between 120 and 139 mmHg, and/or a diastolic blood pressure (DBP) between 80 and 89 mmHg. Prehypertension represents a high risk of developing hypertension and a number of future clinical outcomes, such as coronary artery disease, myocardial infarction, early arteriosclerosis, chronic kidney disease and heart failure (2-8). Schlaich et al (9) and Taddei et al (10) have demonstrated that endothelial dysfunction is critical in the development of essential hypertension. Similarly, the number of senescent endothelial progenitor cells (EPCs) increased in prehypertensive subjects, while the nitric oxide (NO) production is reduced (11). Bone marrow-derived circulating EPCs are involved in the repair of the vascular endothelium, promotion of neovascularization, restoration of endothelial impairment, and amelioration of vascular endothelial function (12,13). A weakened endothelial repair capability, caused by EPC deactivation, may contribute to prehypertension-associated cardiovascular events (11,14).

A lower morbidity of cardiovascular disease (CVD) is observed in premenopausal females in comparison with that in age-matched males; yet, an increase in the incidence of this disease has been reported following menopause, which indicates that estradiol may be a protective factor against CVD (15,16). Seminal studies have revealed that, in postmenopausal females, the increased incidence of CVD is associated with endothelial dysfunction (17,18). Furthermore, apobiotic circulating EPCs have been detected in prehypertensive patients, which are closely associated with endothelial dysfunction (11,14). In vitro, estrogen-treated EPCs exhibited higher migratory and tube-forming capacities, whereas in vivo studies indicated that estrogen was unable to affect the number of circulating EPCs (19). Our earlier study confirmed that highly active circulating EPCs were maintained in prehypertensive premenopausal females (20). However, the number and activity of circulating EPCs in prehypertensive...
postmenopausal females remain undetermined, and the association between flow-mediated dilation (FMD) and the activity of EPCs has yet to be examined.

Earlier studies have demonstrated that nitric oxide (NO), vascular endothelial growth factor (VEGF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) modulate the number and activity of circulating EPCs (21-24). In our previous study (20), the correlation of highly active circulating EPCs in prehypertensive postmenopausal females with NO production was confirmed. Accordingly, the present study aimed to investigate the number and the function of circulating EPCs in subjects with prehypertension and normotension. Additionally, potential sex-associated differences in EPC number and function were examined.

Herein, the levels of NO in the culture medium or plasma, as well as the levels of VEGF and GM-CSF, were determined. Finally, the study explored the association of circulating EPCs with FMD.

Materials and methods

Study population. A total of 80 subjects were enrolled in the present study, including 20 normotensive postmenopausal females, 20 prehypertensive postmenopausal females, 20 normotensive males and 20 prehypertensive males. The prehypertensive subjects exhibited an SBP between 120 and 139 mmHg, and/or a DBP between 80 and 89 mmHg, according to the guidelines established by the eighth report of the JNC (25). All normotensive subjects had an SBP of <120 mmHg and a DBP of <80 mmHg, and presented no cardiovascular risk factors. The subjects recruited into the present study did not suffer from CVD or metabolic disease, as determined by assessment of their entire clinical history and auxiliary examinations. In addition, subject with conditions that may affect the number of EPCs, such as diabetes mellitus, malignant disease, uncontrolled infection and smoking, were excluded. Subjects with previous hysterectomy were also excluded. All subjects were recruited between January 2016 and January 2017, from Xiangya Hospital, Central South University (Changsha, China), and written informed consent was provided for participation. The experimental protocol was approved by The Ethical committee of Xiangya Hospital (ethical license ID of human clinical trial, no. 201503377). The baseline clinical data of the subjects, which were divided into four groups, are listed in Table I.

Clinical measurements. Serum samples were collected in the morning after overnight fasting from the study population (n=80; 40 females and 40 males), and the levels of EPCs, total cholesterol (TC), high-density lipoprotein cholesterol (HDL), low-density lipoprotein cholesterol (LDL), triglycerides (TG) and estradiol were measured. All subjects avoided ingesting alcohol or caffeine for half a day prior to specimen collection. Subjects receiving drug treatments, including antiplatelet agents, anti-inflammatory drugs and hypolipidemic agents, were excluded from the study to reduce potential external effects on the number and activity of circulating EPCs.

EPC isolation, culture and flow cytometric analysis. The number of EPCs in the serum was tested according to previous studies (20,24,26-28). Briefly, Ficoll density gradient centrifugation was used to isolate the peripheral blood mononuclear cells, and then cells were suspended in Endothelial Cell Growth Medium 2 (500 ml; Lonza Group, Ltd., Basel, Switzerland) supplemented with 2% fetal bovine serum (FBS; Sigma-Aldrich; Merck KGaA, Darmstadt, Germany). Next, the cell suspension (2.5x10⁶/ml) was transferred into 25-cm² cell culture flasks (Corning, Inc., Corning, NY, USA), coated with fibronectin (Clonetics Corporation, San Diego, CA, USA), and incubated at 37°C in a humidified atmosphere containing 5% CO₂. After 4 days, nonadherent cells were discarded, while adherent cells were maintained for a further 7 days, and these cells were then utilized in subsequent experiments.

After the 7-day culture, endothelial marker proteins were assessed by flow cytometry. Cell suspension (100 μl) was incubated for 40 min at 4°C with the following primary antibodies: Fluorescein isothiocyanate (FITC) anti-human CD45 (1:10; cat. no. FHF045-025; 4A Biotech, Co., Ltd., Beijing, China), phycoerythrin (PE)-Cy7 anti-human CD34 (1:10; cat. no. FHN034-025; 4A Biotech, Co., Ltd.) and PE-conjugated anti-kinase-insert domain receptor (KDR; 1:20; cat. No. FHK309-025; 4A Biotech, Co., Ltd.). Following erythrocyte lysis, the remaining cells were washed with phosphate-buffered saline (PBS) and fixed in 4% paraformaldehyde for 10 min at 37°C. Flow cytometric analysis was conducted with an ACEA NovoCyte™ flow cytometer (ACEA Biosciences, San Diego, CA, USA), and the results were analyzed with NovoExpress software™ (ACEA Biosciences). The number of circulating EPCs was determined according to the ratio of CD45 CD34⁺/KDR⁺ cells per 100 peripheral blood mononuclear cells.

In order to determine the EPC phenotype, mononuclear cells (2.5x10⁶/ml) were plated on cell culture flasks with endothelial cell growth medium (EGM™-2; Lonza Group, Ltd., Basel, Switzerland). Following 7 days of culturing, the attached endothelial cell-like cells were incubated with DiI-labeled acetylated LDL (Molecular Probes; Thermo Fisher Scientific, Inc.) for 1 h at 37°C. Subsequent to fixing in 4% paraformaldehyde for 30 min at 37°C, the cells were incubated with FITC-labeled lectin (Sigma-Aldrich; Merck KGaA) for 1 h at 37°C. Following incubation with FITC-labeled lectin, the samples were observed under a phase-contrast fluorescence microscope (magnification, x200). Cells presenting double-positive fluorescence were identified as differentiating EPCs by two independent researchers blinded to the study groups.

EPC migration and proliferation assay. The EPC migration and proliferation assays were conducted as previously described (20,24,27-29). In order to determine the cell proliferation, EPCs were harvested by centrifugation at 438 x g for 5 min at 4°C and resuspended in 500 μl EGM-2. A total of 2x10⁴ EPCs/well were added into the upper chamber of a modified Boyden chamber (24-well Costar Transwell plate; pore size, 8 μm; Corning, Inc.), while 500 μl EGM-2 supplemented with 50 ng/ml VEGF was added to the lower chamber. Following incubation at 37°C for 24 h, the lower side of the filter was washed with PBS and fixed with 2% paraformaldehyde for 10 min at 37°C. Cell nuclei were then stained with DAPI. Cells that had migrated into the lower chamber were
manually counted in three random fields under a fluorescence microscope by two independent blinded investigators.

EPC proliferation was determined using an MTT assay. Briefly, EPCs were digested with 0.25% trypsin and then cultured in serum-free medium in a 96-well culture plate (2,000 cells/well) for 24 h. Next, the EPCs were supplemented with 10 µl MTT (5 g/l; Sigma−Aldrich; Merck KGaA, Darmstadt, Germany) and incubated for a further 4 h. The supernatant was then aspirated and discarded. Subsequent to mixing the EPC preparation with 200 µl dimethyl sulfoxide by shaking for 10 min, the optical density value at 490 nm was measured (20,24,28,29).

Detection of plasma NO, VEGF and GM-CSF levels.

The Griess method was used to determine the inactive metabolite of NO in the plasma, as reported in earlier studies (20,24), and the results are expressed as µmol NO x NO₃⁻/NO₂⁻ per liter of medium. In addition, in order to measure the levels of VEGF and GM-CSF in the plasma, high-sensitivity enzyme-linked immunosorbent assay (ELISA; R&D Systems, Inc., Wiesbaden, Germany) was conducted according to the manufacturer's protocol.

Detection of NO, VEGF and GM-CSF secretion by EPCs.

EPCs were cultured in Dulbecco's modified Eagle's medium (Gibco; Thermo Fisher Scientific, Inc.) supplemented with 20% FBS (Sigma-Aldrich; Merck KGaA) for 48 h. Subsequently, in order to measure the levels of NO, VEGF and GM-CSF secretion in the conditioned media of EPCs, the Griess method and ELISA assays were conducted in accordance with the aforementioned protocol.

FMD. The assessment of FMD was performed as described in previous studies (30,31). The brachial artery FMD was assessed by a trained investigator with high-resolution ultrasound using a 5-12-MHz linear transducer on an HDI 5000 system (Philips Medical Systems, Inc., Bothell, WA, USA). After a 15-min rest, the brachial artery was studied at 20-100 mm proximal to the antecubital fossa in supine position. An upper-forearm sphygmomanometer cuff was inflated to raise the pressure to 250 mmHg, and this was maintained for 5 min. The FMD was then calculated as the percentage of increase in the mean diastolic diameter reactive to hyperemia at 55-65 sec after deflation to baseline. After a further 15 min, 400 µg sublingual glyceryl trinitrate was administered, and the diastolic diameter was measured again after 5 min to determine the endothelial independent dilation.

Table I. Clinical and biochemical characteristics of study participants (n=80).

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Normotensive postmenopausal females (n=20)</th>
<th>Prehypertensive postmenopausal females (n=20)</th>
<th>Normotensive males (n=20)</th>
<th>Prehypertensive males (n=20)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>58.8±2.7</td>
<td>57.5±2.8</td>
<td>59.2±3.6</td>
<td>58.5±3.9</td>
</tr>
<tr>
<td>Height (cm)</td>
<td>158.9±5.5</td>
<td>157.9±5.5</td>
<td>165.8±5.6a</td>
<td>167.2±4.7a</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>58.5±3.8</td>
<td>59.0±5.9</td>
<td>63.0±5.9b</td>
<td>66.8±8.5b</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>23.2±1.8</td>
<td>23.6±1.7</td>
<td>22.9±1.6</td>
<td>23.8±2.5</td>
</tr>
<tr>
<td>SBP (mmHg)</td>
<td>108.2±7.2</td>
<td>132.1±4.7a</td>
<td>109.4±6.1</td>
<td>130.1±5.5a</td>
</tr>
<tr>
<td>DBP (mmHg)</td>
<td>67.4±4.5</td>
<td>82.1±4.4a</td>
<td>68.8±4.8</td>
<td>80.0±4.0a</td>
</tr>
<tr>
<td>HR (beats/min)</td>
<td>75.7±8.8</td>
<td>73.5±6.3</td>
<td>76.7±8.9</td>
<td>77.2±7.4</td>
</tr>
<tr>
<td>AST (mmol/l)</td>
<td>21.9±5.3</td>
<td>22.5±6.1</td>
<td>23.2±5.7</td>
<td>24.1±5.2</td>
</tr>
<tr>
<td>ALT (mmol/l)</td>
<td>20.6±5.9</td>
<td>20.8±4.7</td>
<td>21.2±6.3</td>
<td>23.6±5.6</td>
</tr>
<tr>
<td>BUN (mmol/l)</td>
<td>5.5±0.7</td>
<td>5.2±1.0</td>
<td>5.4±1.0</td>
<td>5.5±0.7</td>
</tr>
<tr>
<td>Cr (mmol/l)</td>
<td>68.1±11.5</td>
<td>65.9±11.9</td>
<td>70.6±11.5</td>
<td>71.9±11.8</td>
</tr>
<tr>
<td>LDL (mmol/l)</td>
<td>2.72±0.40</td>
<td>2.67±0.43</td>
<td>2.57±0.39</td>
<td>2.74±0.37</td>
</tr>
<tr>
<td>TC (mmol/l)</td>
<td>4.55±0.67</td>
<td>4.46±0.54</td>
<td>4.33±0.54</td>
<td>4.61±0.53</td>
</tr>
<tr>
<td>HDL (mmol/l)</td>
<td>1.48±0.22</td>
<td>1.50±0.22</td>
<td>1.52±0.20</td>
<td>1.45±0.17</td>
</tr>
<tr>
<td>TG (mmol/l)</td>
<td>1.37±0.19</td>
<td>1.35±0.20</td>
<td>1.31±0.16</td>
<td>1.38±0.18</td>
</tr>
<tr>
<td>FPG (mmol/l)</td>
<td>4.73±0.50</td>
<td>4.60±0.47</td>
<td>4.45±0.53</td>
<td>4.63±0.44</td>
</tr>
<tr>
<td>FMD (%)</td>
<td>7.54±1.77</td>
<td>5.72±1.28a</td>
<td>7.49±1.55b</td>
<td>5.38±1.46c,b</td>
</tr>
</tbody>
</table>

*P<0.05 vs. normotensive subjects in the same sex group; †P<0.05 vs. postmenopausal females in the corresponding normotensive or prehypertensive group. Data are presented as the mean ± standard deviation. BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic pressure; HR, heart rate; AST, aspartate transaminase; ALT, alanine aminotransferase; BUN, blood urea nitrogen; Cr, creatinine; LDL, low-density lipoprotein; TC, total cholesterol; HDL, high-density lipoprotein; TG, triglyceride; FPG, fasting plasma glucose; FMD, flow-mediated dilation.

Statistical analysis. All data were analyzed using the SPSS statistical software package, version 11.0 (SPSS, Inc., Chicago, IL, USA), and are presented as the mean ± standard deviation. Two-way analysis of variance was used to compare between the four groups. When a significant F-value was observed, the Newman-Keuls method was applied as a post hoc test to identify differences among mean values. Univariate correlations were examined by Pearson's correlation coefficient method.
A P-value of <0.05 was considered to denote a difference that was statistically significant.

**Results**

**Clinical baseline characteristics.** The essential characteristics of the study population are summarized in Table I. No marked differences were observed with regard to the patient age and body mass index among the subjects. The SBP and DBP values were markedly lower in normotensive males and normotensive postmenopausal females as compared with those in prehypertensive subjects of the same sex, respectively. However, the levels of TC, HDL, LDL, TG and plasma glucose were similar among the four groups. Furthermore, FMD in prehypertensive postmenopausal females was significantly lower in comparison with that in normotensive postmenopausal females. Similarly, FMD was lower in prehypertensive males as compared with that in normotensive males. Additionally, FMD in postmenopausal females was increased compared with male subjects, regardless of the level of blood pressure.

**Number and activity of circulating EPCs.** To determine whether the circulating EPC was associated with prehypertension, their number and activity was determined. The results shown in Fig. 1 indicated that there was no significant difference in circulating EPCs between normotensive and prehypertensive postmenopausal females, or between normotensive and prehypertensive males. In addition, no notable difference was detected in circulating EPCs between normotensive males and females (postmenopausal), or between prehypertensive males and females (postmenopausal). Furthermore, the number of EPCs determined by the cell culture assay exhibited no significant difference among the four groups.

The migration and proliferation of EPCs were then examined, and the results are shown in Fig. 2. As compared with normotensive postmenopausal females or males, the migration of EPCs was attenuated in the prehypertensive postmenopausal females and males, respectively. Similarly, the proliferation of EPCs in normotensive subjects was significantly higher compared with that of prehypertensive subjects in the same sex group, respectively. However, no marked difference in migration and proliferation of circulating EPCs was observed between normotensive males and females, or between prehypertensive males and females.

**Plasma levels of NO, VEGF and GM-CSF.** To investigate the mechanism leading to differences in the activity of circulating EPCs, the levels of certain factors present in the plasma influencing the function of EPCs were examined. The levels of NO, VEGF and GM-CSF detected in the plasma of the four groups are displayed in Fig. 3. As shown in Fig. 3A, the plasma NO level in postmenopausal females with prehypertension or
Figure 2. Activity of circulating EPCs. (A) Migratory and (B) proliferative activities of circulating EPCs. The EPC function in prehypertensive males and postmenopausal females was weaker compared with that in normotensive males and females (postmenopausal), respectively. However, the EPC activities were not markedly different between normotensive males and females, and between prehypertensive males and females (postmenopausal), respectively. Data are presented as the mean ± standard deviation. *P<0.05 vs. normotensive subjects in the same sex group. EPCs, endothelial progenitor cells.

Figure 3. Plasma levels of NO, VEGF and GM-CSF. (A) Plasma NO levels in prehypertensive males and females (postmenopausal) was markedly lower in comparison with that in normotensive males and females (postmenopausal), whereas no difference was detected between the two normotensive or the two prehypertensive groups. (B) VEGF and (C) GM-CSF levels in the plasma did not differ significantly among the four groups. Data are presented as the mean ± standard deviation. *P<0.05 vs. normotensive subjects in the same sex group. EPCs, endothelial progenitor cells; NO, nitric oxide; VEGF, vascular endothelial growth factor; GM-CSF, granulocyte-macrophage colony-stimulating factor.
prehypertensive males was significantly lower compared with that in normotensive postmenopausal females or normotensive males, respectively. However, the plasma level of NO presented no notable difference between the two prehypertensive males or postmenopausal females, and between the two normotensive groups. As exhibited in Fig. 3B, the plasma VEGF level did not significantly differ in any of the four groups. Similar to VEGF, the plasma GM-CSF level shown in Fig. 3C exhibited no evident difference among the four groups.

**Discussion**

In the present study, it was demonstrated that the proliferation and the migration of EPCs were decreased in prehypertensive postmenopausal females relative to the normotensive postmenopausal females, although there was no significant change in the number of EPCs. This phenomenon was also observed between normotensive and prehypertensive males. The data also verified that the NO level in the plasma and NO secretion by EPCs declined in both prehypertensive postmenopausal females and age-matched males, as compared with the corresponding normotensive groups. This indicated that circulating NO level and the NO secretion function of EPCs may be connected to pathophysiological processes of prehypertension. In addition, the positive correlation of FMD with both circulating EPC function (migration and proliferation) and NO production was confirmed. These results are concordant with the findings of our previous study (20). The previous study reported that an increased number and activity of EPCs in premenopausal females in comparison with age-matched males. However, in the present study, there was no evidence that the activity and number of EPCs differed between

---

**Figure 4. NO, VEGF and GM-CSF secretion by EPCs.** (A) NO secretion by EPCs in prehypertensive males and females was significantly lower compared with that in normotensive males and females, respectively. By contrast, no difference was detected in NO secretion by EPCs between the normotensive males and females, or between the prehypertensive males and females. (B) VEGF and (C) GM-CSF secretion by EPCs did not differ significantly among the four groups. Data are given as the mean ± standard deviation. *P<0.05 vs. normotensive subjects in the same sex group. EPCs, endothelial progenitor cells; NO, nitric oxide; VEGF, vascular endothelial growth factor; GM-CSF, granulocyte-macrophage colony-stimulating factor.
prehypertensive males and prehypertensive postmenopausal females, which implied that prehypertensive postmenopausal females may have the same cardiovascular risk as age-matched males. Thus, it can be inferred that, as females enter menopause, the EPC function may decrease, which may result in an increase in the cardiovascular risk owing to estradiol decline.

In patients with prehypertension, the migratory and proliferative abilities of circulating EPCs are attenuated, suggesting that EPCs are involved in the pathogenesis of prehypertension through affecting endothelial repair (11,14). It is widely accepted that prehypertensive premenopausal females have more active circulating EPCs in comparison with age-matched males, indicating that sex difference may serve a dominant role in prehypertension-associated endothelial dysfunction at a young age (32-35). Our previous study has demonstrated the improved activity of circulating EPCs in prehypertensive premenopausal females as compared with that in young males, which was associated with higher NO levels in the plasma and NO production by circulating EPCs (20). There is a rational hypothesis is that estradiol may be involved in vascular protection through regulating EPC function. In the present study, attenuated activity of EPCs was observed in prehypertensive postmenopausal females, which appeared to disagree with the findings of our previous study in premenopausal females (20). Furthermore, the alterations in EPC function between prehypertensive and normotensive subjects were detected in males and females. The present results revealed that vascular dysfunction in prehypertensive postmenopausal females may be linked to decreasing EPC-mediated endogenous endothelial repair capacity caused by the decrease in the estradiol-protective effects against CVD.

Numerous studies have indicated that NO, VEGF and GM-CSF can modulate the amount and activity of circulating EPCs (21-24). Endogenous NO biosynthesis has a significant effect on the biological function of EPCs (36). The modulation of NADPH oxidase 2 in human EPCs can restore its physiological function and properties (37). During prehypertension, NO production by early EPCs, which is associated with EPC-mediated endothelial repair capacity (38,39), is markedly decreased (11). In our previous study, it was confirmed that the preserved NO production was associated with elevated circulating EPCs in prehypertensive premenopausal females, rather than VEGF and GM-CSF (20). In the present study, it was further demonstrated that the NO level and NO production in prehypertensive postmenopausal females were similar to those of prehypertensive age-matched males. Furthermore, the VEGF or GM-CSF levels did not differ among the groups, suggesting that the attenuated EPC function in prehypertensive postmenopausal females was independent of alterations in VEGF and GM-CSF levels.

The mechanism of lower NO secretion by EPCs has yet to be defined. However, estrogen may account for the difference in endothelial NO release between males and females (40-42), which may promote NO production via the upregulation of endothelial NO synthase (eNOS) expression, protection against destabilization of eNOS mRNA (43), exertion of antioxidant effects (44), activation of the PI3K/Akt pathway (45), and upregulation of Mas receptor (46).
addition, it is presumed that the mechanism may be involved in eNOS expression, which should be discussed in further studies. Apparent discrepancies in EPC function between prehypertensive postmenopausal females and prehypertensive premenopausal females may be due to the pivotal role of estradiol in EPC function protection. Along with the results of previous studies, it can be concluded that the gender difference in EPC function disappears when females enter post-menopause. Furthermore, it is considered that EPC-mediated endothelial repair capacity and endothelium-dependent dilation are impaired in postmenopausal females as a result of the decrease in the estradiol-protective effects against CVD. Thus, the perimenopausal period may be critical for early intervention in prehypertension therapy.

In conclusion, the current study demonstrated that the gender difference in endothelial function and circulating EPCs disappeared in prehypertensive postmenopausal females, which may be associated with the decline in NO production. The attenuated endogenous endothelial repair capacity partly elucidates the decreased endothelial protection in postmenopause. The present findings may provide novel targets for rescuing endothelial dysfunction accompanied by postmenopause and prehypertension.

Acknowledgements

Not applicable.

Funding

The study was financially supported by grants from the National Natural Scientific Foundation of China (nos. 81570461).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

CL designed the project. WW, DH, ZW and LL performed the experiments, and collected, analyzed and interpreted the data, as well as generated the figures. WW, LL and ZW wrote the manuscript.

Ethics approval and consent to participate

The experimental protocol was approved by The Ethical committee of Xiangya Hospital (ethical license ID of human clinical trial, no. 201503377). Written informed consent was provided for participation.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References


